Lilly settles Mississippi lawsuit for more than $18 million

Eli Lilly & Co. will pay $18.5 million to end Mississippi’s case against it for promotional claims related to the anti-psychotic drug Zyprexa, according to an announcement made by state Attorney General Jim Hood at the end of January.
Register for free to listen to this article
Listen with Speechify
0:00
1:00
JACKSON, Miss.—Eli Lilly & Co. will pay $18.5 million toend Mississippi's case against it for promotional claims related to theanti-psychotic drug Zyprexa, according to an announcement made by stateAttorney General Jim Hood at the end of January. Under the settlement, Lillyagreed to curb marketing activities and payments to healthcare professionalsfor non-approved uses Zyprexa, which is approved for the treatment of bipolardisorders. Lilly had been accused of promoting the drug for any kind ofdepression. In the 23-page settlement, Lilly did not admit that it violated anystate consumer protection laws and said it had not committed any "liability,fault or wrongdoing." The agreement with the Attorney General's Office does notprotect Lilly from criminal allegations.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue